EGFR-expressing KRAS wild-type mCRC: first-line treatment in combination with FOLFIRI; in combination with irinotecan when pts are refractory to irinotecan-based chemotherapy; and as a single agent in pts who have failed oxaliplatin- and irinotecan-based chemotherapy and who are intolerant to irinotecanSCCHN: in combination with radiation therapy for pts with locally or regionally advanced SCCHN; in combination with platinum-based chemotherapy for pts with recurrent locoregional or metastatic SCCHN; and for pts with recurrent or metastatic SCCHN who are intolerant to irinotecan. Here, KRAS is linked to head and neck squamous cell carcinoma.